Fulcrum Therapeutics, Inc. (FULC) vs Upstream Bio, Inc. (UPB)

Fulcrum Therapeutics, Inc. and Upstream Bio, Inc. are both Biotechnology companies. Fulcrum Therapeutics, Inc. and Upstream Bio, Inc. are of similar size ($288.8M and $283.2M). Fulcrum Therapeutics, Inc. grew revenue faster over the last twelve months: 1,939.8% against 16.0%. Fulcrum Therapeutics, Inc. has the higher net margin (0.00% vs −4,955.7%) and the higher return on invested capital (0.00% vs −1,100.9%). Across the 15 metrics below, Fulcrum Therapeutics, Inc. leads on 13 and Upstream Bio, Inc. on 2.

Valuation

Metric FULC UPB Biotechnology median
P/E n/m n/m 7.88
P/S 3.46 92.62 11.47
P/B 0.92 1.08 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 0.35 n/m 0.74
EV/Sales (0.41) 9.87 10.73
Earnings yield (32.35%) (54.10%) (28.84%)
Free cash flow yield (23.03%) (46.74%) (23.03%)

Profitability

Metric FULC UPB Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin 0.00% (5,382.65%) 0.00%
Net margin 0.00% (4,955.67%) 0.00%
Free cash flow margin 0.00% (4,317.42%) 0.00%
Return on equity (32.38%) (46.05%) (57.72%)
Return on assets (30.75%) (44.61%) (49.22%)
Return on invested capital 0.00% (1,100.93%) 0.00%

Growth

Metric FULC UPB Biotechnology median
Revenue growth (TTM) 1,939.80% 15.98% 5.64%
EPS growth (last fiscal year) (637.50%) 52.33% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric FULC UPB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 31.35 27.99 4.73
Net debt to EBITDA 4.23 2.11 0.96

Dividend

Metric FULC UPB Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric FULC UPB Biotechnology median
Market cap 288.79m 283.17m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack